6479720
Last Update Posted: 2024-12-16
Recruiting
Females accepted | 40 Years-90 Years |
300 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Efficacy of Solifenacin or Mirabegron with Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Women with detrusor overactivity who were refractory to anti-muscarinics or mirabegron were enrolled for prospective study. Patients were divided into three groups: combined pharmacotherapy with solifenacin and mirabegron, solifenacin with vaginal estrogen cream and mirabegron with vaginal estrogen cream. Incontinence-related symptoms distress and impact on quality of life were evaluated by short form of Urinary Distress Inventory, (UDI-6), Incontinence Impact Questionnaire (IIQ-7) and Overactive Bladder Symptom Score (OABSS). Objective outcomes include changes from baseline in episodes of daily micturition, urgency, urinary incontinence and nocturia.
Eligibility
Relevant conditions:
Effect of Drug
Urinary Bladder, Overactive
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov